Le Lézard
Classified in: Health, Sports and recreation
Subject: CSR

BMO Ride for Cancer surpasses more than $10M net raised for local cancer care since 2015, hits record-breaking fundraising total despite tropical storm pivot

HALIFAX, NS, Sept. 25, 2023 /CNW/ - BMO Ride for Cancer reached a historic milestone this weekend as Atlantic Canada's largest cycling fundraising event celebrated over $10 million net raised since 2015 for local cancer care.

The annual event ? which took place on Saturday, September 23 ? was forced to pivot due to trail and road damages from the recent post-tropical storm Lee; cancelling the cycling component for the first time in its nine-year history. Despite this obstacle, the BMO Ride for Cancer community rallied like never before ? raising a record-breaking $2,372,669 million net in 2023.

These funds mean the ninth annual BMO Ride for Cancer event has fully funded Atlantic Canada's first and only CAR-T therapy lab at the QEII Health Sciences Centre. This revolutionary and lifesaving immunotherapy is a final lifeline and potential cure for certain blood cancer patients who've tried all other treatment options.

1,200 individuals, including participants, their loved ones and event volunteers, came together for an in-person BMO Ride Celebration Festival on Saturday at event grounds (Hobsons Lake Drive, Bayers Lake) ? recognizing the incredible efforts of the community and the life-changing impact it'll have on Atlantic Canadians facing a cancer diagnosis.

Quick facts

"Though we faced an incredible challenge this year due to event route damages, our BMO Ride community persevered and demonstrated how they're truly an unstoppable force. With a record-smashing $2,372,669 net raised ? our most successful year ever ? we are making Atlantic Canada's first CAR-T therapy lab a reality. As we celebrate this transformational impact on cancer care at the QEII, we're already looking ahead to the tenth annual BMO Ride for Cancer in 2024, where we'll come back stronger than ever before." ? Catherine Campbell, volunteer chair of engagement, BMO Ride for Cancer.

"When I started participating in BMO Ride for Cancer five years ago, I thought the event proceeds might one day impact someone I know or love; I never imagined that it would eventually be me. Last December at 41 years old, I was diagnosed with colorectal cancer. As a BMO Ride participant and current cancer patient at the QEII, I've seen firsthand the direct impact this event has on the treatments and cancer journeys of patients like me." ? Liz Sequeira, participant, BMO Ride for Cancer.

"As host of BMO Ride for Cancer, the QEII Foundation is incredibly grateful to BMO, our event participants, donors, volunteers, sponsors, community partners and more who made Saturday, September 23 a monumental success. It's not about the where or the how, it's the why and this past week has demonstrated that BMO Ride for Cancer is so much more than a bike ride; it's a movement for local cancer care that our community has fully embraced. With more than $10 million net raised since 2015, the impact of BMO Ride for Cancer is felt far and wide at Atlantic Canada's largest and most specialized cancer centre, the QEII." ? Susan Mullin, President and CEO, QEII Foundation


These press releases may also interest you

9 déc 2023
Advancing Health Boundaries: Harnessing the Power of CD34 Stem Cells!At the forefront of a natural and safe revolution in stem cell supplementation, Beauty-Stem...

9 déc 2023
Four studies presented during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition examine how demographics and other characteristics of patients and researchers play into inequities in health outcomes in the context of blood...

9 déc 2023
Researchers report striking progress in the application of cutting-edge tools and treatments to address longstanding challenges in blood disorders and related health conditions in four studies presented during the 65th American Society of Hematology...

9 déc 2023
Researchers report significant progress toward improving access to effective interventions to address blood disorders and promote healthy blood cell functioning in four studies presented during the 65th American Society of Hematology (ASH) Annual...

9 déc 2023
Pfizer Inc. today presented results from the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab for the treatment of people with severe hemophilia A and moderately severe to severe hemophilia B without inhibitors to Factor...

9 déc 2023
Reporting Complete Response Data from the Ongoing APTIVATE International Phase 1/2 Study of Tuspetinib (TUS) in Relapsed/Refractory AML PatientsTUS Single Agent and TUS/VEN Combination Demonstrate Favorable Safety and Tolerability TUS/VEN Combination...

News published on and distributed by: